Low serum bilirubin concentration is a predictor of chronic kidney disease

Atherosclerosis

Volumn 234, Issue 2, 2014, Pages 421-425

  Tanaka, Muhei ^a   Fukui, Michiaki ^a   Okada, Hiroshi ^a   Senmaru, Takafumi ^a   Asano, Mai ^a   Akabame, Satoshi ^b   Yamazaki, Masahiro ^a   Tomiyasu, Ki ichiro ^b   Oda, Yohei ^a   Hasegawa, Goji ^a   Toda, Hitoshi ^c   Nakamura, Naoto ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b Yamashiro Public Hospital   (Japan)

^c Oike Clinic   (Japan)

Author keywords

Antioxidant; Bilirubin; Chronic kidney disease

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CREATININE; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; URIC ACID; BIOLOGICAL MARKER;

ADULT; AGE; ARTICLE; BILIRUBIN BLOOD LEVEL; BODY MASS; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; DYSLIPIDEMIA; FEMALE; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; POPULATION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; SYSTOLIC BLOOD PRESSURE; BLOOD; DOWN REGULATION; EPIDEMIOLOGY; HEALTH SURVEY; JAPAN; KIDNEY; PATHOPHYSIOLOGY; PROGNOSIS; RENAL INSUFFICIENCY, CHRONIC;

ADULT; BILIRUBIN; BIOLOGICAL MARKERS; DISEASE PROGRESSION; DOWN-REGULATION; FEMALE; GLOMERULAR FILTRATION RATE; HEALTH SURVEYS; HUMANS; JAPAN; KIDNEY; MALE; MIDDLE AGED; PROGNOSIS; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS;

EID: 84900861689     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2014.03.015     Document Type: Article

References (42)

1. Eknoyan G., Lameire N., Barsoum R., Eckardt K.U., Levin A., Levin N., et al. The burden of kidney disease: improving global outcomes. Kidney Int 2004, 66:1310-1314.
2. Go A.S., Chertow G.M., Fan D., McCulloch C.E., Hsu C.Y. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. NEngl J Med 2004, 351:1296-1305.
3. Stocker R., Glazer A.N., Ames B.N. Antioxidant activity of albumin-bound bilirubin. Proc Natl Acad Sci USA 1987, 84:5918-5922.
4. Lanone S., Bloc S., Foresti R., Almolki A., Taillé C., Callebert J., et al. Bilirubin decreases nos2 expression via inhibition of NAD(P)H oxidase: Implications for protection against endotoxic shock in rats. FASEB J 2005, 19:1890-1892.
5. Sano K., Nakamura H., Matsuo T. Mode of inhibitory action of bilirubin on protein kinase c. Pediatr Res 1985, 19:587-590.
6. Schwertner H.A., Jackson W.G., Tolan G. Association of low serum concentration of bilirubin with increased risk of coronary artery disease. Clin Chem 1994, 40:18-23.
7. Breimer L.H., Wannamethee G., Ebrahim S., Shaper A.G. Serum bilirubin and risk of ischemic heart disease in middle-aged British men. Clin Chem 1995, 41:1504-1508.
8. Perlstein T.S., Pande R.L., Beckman J.A., Creager M.A. Serum total bilirubin level and prevalent lower extremity peripheral arterial disease: National Health and Nutrition Examination Survey (NHANES) 1999 to 2004. Arterioscler Thromb Vasc Biol 2008, 28:166-172.
9. Adin C.A., Croker B.P., Agarwal A. Protective effects of exogenous bilirubin on ischemiareperfusion injury in the isolated, perfused rat kidney. Am J Physiol Renal Physiol 2005, 288:F778-F784.
10. Matsuo S., Imai E., Horio M., Yasuda Y., Tomita K., Nitta K., et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009, 53:982-992. Collaborators developing the Japanese equation for estimated GFR. Collaborators developing the Japanese equation for estimated GFR.
11. Ishani A., Grandits G.A., Grimm R.H., Svendsen K.H., Collins A.J., Prineas R.J., et al. Association of single measurements of dipstick proteinuria, estimated glomerular filtration rate, and hematocrit with 25-year incidence of end-stage renal disease in the multiple risk factor intervention trial. JAm Soc Nephrol 2006, 17:1444-1452.
12. Matsushita K., van der Velde M., Astor B.C., Woodward M., Levey A.S., de Jong P.E., et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 2010, 375:2073-2081. Chronic Kidney Disease Prognosis Consortium.
13. Sarnak M.J., Levey A.S., Schoolwerth A.C., Coresh J., Culleton B., Hamm L.L., et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003, 108:2154-2169. American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention.
14. Keith D.S., Nichols G.A., Gullion C.M., Brown J.B., Smith D.H. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med 2004, 164:659-663.
15. Evans M., Fryzek J.P., Elinder C.G., Cohen S.S., McLaughlin J.K., Nyrén O., et al. The natural history of chronic renal failure: results from an unselected, population-based, inception cohort in Sweden. Am J Kidney Dis 2005, 46:863-870.
16. Erdogan D., Gullu H., Yildirim E., Tok D., Kirbas I., Ciftci O., et al. Low serum bilirubin levels are independently and inversely related to impaired flow-mediated vasodilation and increased carotid intima-media thickness in both men and women. Atherosclerosis 2006, 184:431-437.
17. Vítek L., Jirsa M., Brodanová M., Kalab M., Marecek Z., Danzig V., et al. Gilbert syndrome and ischemic heart disease: a protective effect of elevated bilirubin levels. Atherosclerosis 2002, 160:449-456.
18. Vítek L., Novotný L., Sperl M., Holaj R., Spácil J. The inverse association of elevated serum bilirubin levels with subclinical carotid atherosclerosis. Cerebrovasc Dis 2006, 21:408-414.
19. Torgerson J.S., Lindroos A.K., Sjöström C.D., Olsson R., Lissner L., Sjöström L. Are elevated aminotransferases and decreased bilirubin additional characteristic of the metabolic syndrome?. Obes Res 1997, 5:105-114.
20. Fukui M., Tanaka M., Shiraishi E., Harusato I., Hosoda H., Asano M., et al. Relationship between serum bilirubin and albuminuria in patients with type 2 diabetes. Kidney Int 2008, 74:1197-1201.
21. Stocker R., Yamamoto Y., McDonagh A.F., Glazer A.N., Ames B.N. Bilirubin is an antioxidant of possible physiological importance. Science 1987, 235:1043-1046.
22. Kumar A., Pant P., Basu S., Rao G.R., Khanna H.D. Oxidative stress in neonatal hyperbilirubinemia. JTrop Pediatr 2007, 53:69-71.
23. Kao M.P., Ang D.S., Pall A., Struthers A.D. Oxidative stress in renal dysfunction: mechanisms, clinical sequelae and therapeutic options. JHum Hypertens 2010, 24:1-8.
24. Matsumoto H., Ishikawa K., Itabe H., Maruyama Y. Carbon monoxide and bilirubin from heme oxygenase-1 suppresses reactive oxygen species generation and plasminogen activator inhibitor-1 induction. Mol Cell Biochem 2006, 291:21-28.
25. Jiang F., Roberts S.J., Datla Sr, Dusting G.J. NO modulates NADPH oxidase function via heme oxygenase-1 in human endothelial cells. Hypertension 2006, 48:950-957.
26. Datla S.R., Dusting G.J., Mori T.A., Taylor C.J., Croft K.D., Jiang F. Induction of heme oxygenase-1 invivo suppresses NADPH oxidase derived oxidative stress. Hypertension 2007, 50:636-642.
27. Vera T., Stec D.E. Moderate hyperbilirubinemia improves renal hemodynamics in ANG II-dependent hypertension. Am J Physiol Regul Integr Comp Physiol 2010, 299:R1044-R1049.
28. Vera T., Granger J.P., Stec D.E. Inhibition of bilirubin metabolism induces moderate hyperbilirubinemia and attenuates ANG II-dependent hypertension in mice. Am J Physiol Regul Integr Comp Physiol 2009, 297:R738-R743.
29. Nakagami T., Toyomura K., Kinoshita T., Morisawa S. Abeneficial role of bile pigments as an endogenous tissue protector: anti-complement effects of biliverdin and conjugated bilirubin. Biochim Biophys Acta 1993, 1158:189-193.
30. Mietus-Snyder M., Friera A., Glass C.K., Pitas R.E. Regulation of scavenger receptor expression in smooth muscle cells by protein kinase c: a role for oxidative stress. Arterioscler Thromb Vasc Biol 1997, 17:969-978.
31. Mazzone G.L., Rigato I., Ostrow J.D., Bossi F., Bortoluzzi A., Sukowati C.H., et al. Bilirubin inhibits the TNFalpha-related induction of three endothelial adhesion molecules. Biochem Biophys Res Commun 2009, 386:338-344.
32. Yilmaz M.B., Biyikoglu S.F., Akin Y., Guray U., Kisacik H.L., Korkmaz S. Obesity is associated with impaired coronary collateral vessel development. Int J Obes 2003, 27:1541-1545.
33. Davignon J., Ganz P. Role of endothelial dysfunction in atherosclerosis. Circulation 2004, 109:III27-32.
34. Vanhoutte P.M. The endothelium-modulator of vascular smooth-muscle tone. NEngl J Med 1988, 319:512-513.
35. Recio-Mayoral A., Banerjee D., Streather C., Kaski J.C. Endothelial dysfunction, inflammation and atherosclerosis in chronic kidney disease-a cross-sectional study of predialysis, dialysis and kidney-transplantation patients. Atherosclerosis 2011, 216:446-451.
36. Djousse L., Levy D., Cupples A., Evans J.C., D'Agostino R.B., Ellison R.C. Total serum bilirubin and risk of cardiovascular disease in the Framingham offspring study. Am J Cardiol 2001, 87:1196-1200.
37. Li Y., Meng S.Y., Meng C.C., Yu W.G., Wang R.T. Decreased serum bilirubin is associated with arterial stiffness in men. Nutr Metab Cardiovasc Dis 2013, 23:375-381.
38. Hopkins P.N., Wu L.L., Hunt S.C., James B.C., Vincent G.M., Williams R.R. Higher serum bilirubin is associated with decreased risk for early familial coronary artery disease. Arterioscler Thromb Vasc Biol 1996, 16:250-255.
39. Schwertner H.A. Association of smoking and low serum bilirubin antioxidant concentrations. Atherosclerosis 1998, 136:383-387.
40. Wu T.W., Fung K.P., Wu J., Yang C.C., Weisel R.D. Antioxidation of human low density lipoprotein by unconjugated and conjugated bilirubins. Biochem Pharmacol 1996, 51:859-862.
41. McCarty M.F. Iatrogenic Gilbert syndrome. A strategy for reducing vascular and cancer risk by increasing plasma unconjugated bilirubin. Med Hypotheses 2007, 69:974-994.
42. Multiple risk factor intervention trial: risk factor changes in mortality results. JAm Med Assoc 1982, 248:1465-1470. Multiple Risk Factor Intervention Trial Research Group.